Lexeo Therapeutics, Inc.
LXEO
$4.71
$0.7819.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 74.09M | 63.94M | 57.76M | 52.43M | 53.13M |
| Gross Profit | -74.09M | -63.94M | -57.76M | -52.43M | -53.13M |
| SG&A Expenses | 31.68M | 29.42M | 24.33M | 20.08M | 15.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.77M | 93.36M | 82.09M | 72.51M | 68.51M |
| Operating Income | -105.77M | -93.36M | -82.09M | -72.51M | -68.51M |
| Income Before Tax | -98.33M | -86.60M | -77.22M | -69.42M | -66.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -98.33 | -86.60 | -77.22 | -69.42 | -66.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.33M | -86.60M | -77.22M | -69.42M | -66.39M |
| EBIT | -105.77M | -93.36M | -82.09M | -72.51M | -68.51M |
| EBITDA | -105.14M | -92.73M | -81.46M | -71.91M | -67.94M |
| EPS Basic | -3.09 | -3.17 | -14.64 | -22.30 | -33.11 |
| Normalized Basic EPS | -1.93 | -1.98 | -9.15 | -13.94 | -20.69 |
| EPS Diluted | -3.09 | -3.17 | -14.64 | -22.30 | -33.11 |
| Normalized Diluted EPS | -1.93 | -1.98 | -9.15 | -13.94 | -20.69 |
| Average Basic Shares Outstanding | 127.12M | 110.48M | 79.05M | 47.66M | 21.30M |
| Average Diluted Shares Outstanding | 127.12M | 110.48M | 79.05M | 47.66M | 21.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |